Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.

@article{Lin2011SystematicRO,
  title={Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.},
  author={Jennifer S. Lin and Elizabeth M Webber and Caitlyn A Senger and Rebecca S Holmes and Evelyn P. Whitlock},
  journal={American journal of cancer research},
  year={2011},
  volume={1 5},
  pages={
          650-62
        }
}
Pharmacogenetic testing can help identify patients with metastatic colorectal cancer more likely to respond to anti-EGFR therapy. We systematically reviewed the benefits and harms of EGFR-related pharmacogenetic testing of molecular targets downstream to KRAS in the treatment of metastatic colorectal cancer. We searched five electronic databases from January 2000 through November 2010, and conducted separate grey literature and conference abstracts searches. Two reviewers independently assessed… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

K-RAS and N-RAS mutations in testicular germ cell tumors.

  • Bosnian journal of basic medical sciences
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

EGFR-related genetic testing in metastatic colorectal cancer

O Bouche, J Reid, +15 authors F. Penault- Llorca
  • Am J Cancer Res
  • 2009
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

PTEN status in advanced colorectal cancer treated with cetuximab

  • British Journal of Cancer
  • 2010
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL